novel CD19/BCMA dual targeting allogeneic CAR T cell therapy(Juventas Cell Therapy)

N/A

Report date: 2024/12/26 10:30:46

Base Information

Drug Namenovel CD19/BCMA dual targeting allogeneic CAR T cell therapy(Juventas Cell Therapy)
Drug Alias NameHY034HY-034
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein modulatorsB-lymphocyte antigen CD19 modulators
TargetsB-cell maturation proteinB-lymphocyte antigen CD19
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJuventas Cell Therapy Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJuventas Cell Therapy Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A